Notice of Annual General Meeting 2023 - Clarification (ASX Announcement)

Nov 15th, 2023

Starpharma refers to its Notice of Annual General Meeting dated 27 October 2023 (Notice).

Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)

Nov 14th, 2023

Starpharma has been invited to present today at the Bell Potter Healthcare Conference, a virtual investor conference that showcases Australia's leading healthcare companies to institutional investors and Bell Potter’s retail network.

Starpharma announces new CEO, Ms Cheryl Maley (ASX Announcement)

Nov 10th, 2023

Starpharma is today pleased to announce the appointment of Ms Cheryl Maley as Chief Executive Officer (CEO) and Managing Director of Starpharma effective 8 January 2024.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Oct 31st, 2023

Starpharma today releases its Quarterly Activities Report and Appendix 4C for the period ended 30 September 2023 (Q1 FY24).

SPL to present DEP radiotheranostics at Wilsons Conference (ASX Announcement)

Oct 26th, 2023

Starpharma today announces that it will present at the Wilsons Drug and Device Conference tomorrow, 27 October 2023, at 10:00 AM AEST.

Starpharma receives $7.2 million R&D Tax Incentive refund (ASX Announcement)

Oct 23rd, 2023

Starpharma today announces it has received a $7.2 million research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme.

Positive DEP® Cabazitaxel Phase 2 Results in Multiple Cancers (ASX Announcement)

Oct 18th, 2023

Starpharma today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP^® cabazitaxel. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP^® cabazitaxel in advanced, metastatic castrate-resistant prostate cancer (mCRPC), as well as other difficult-to-treat cancers, including platinum-resistant ovarian cancer and gastro-oesophageal cancers.

DEP® irinotecan IO/PARP combination data presented at AACR (ASX Announcement)

Oct 16th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® irinotecan combination data poster, showcasing the recently announced1 data for DEP® irinotecan in combination with leading anticancer therapies, including immuno-oncology (IO) agents, in human colorectal cancer (CRC) models.

DEP® irinotecan clinical data presented at AACR meeting (ASX Announcement)

Oct 16th, 2023

Starpharma today provides a copy of the DEP® irinotecan clinical poster, highlighting the recently announced1 positive interim clinical data from Starpharma’s Phase 1/2 clinical trial, which demonstrated durable anti-tumour responses in advanced colorectal cancer (CRC) and platinum-resistant/refractory ovarian cancer.

DEP® theranostic presented at international oncology meeting (ASX Announcement)

Oct 16th, 2023

Starpharma today provides a copy of the poster that showcases the results from a study of DEP® HER2-zirconium, Starpharma’s HER2-targeted radiodiagnostic candidate, which demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER2+ breast cancer model.

Date of Starpharma’s Annual General Meeting 2023 (ASX Announcement)

Oct 2nd, 2023

Starpharma today announces, in accordance with ASX Listing Rule 3.13.1, that its 2023 Annual General Meeting (AGM) will be held at 2:00 p.m. (Melbourne time) on Wednesday, 29 November 2023.

DEP® irinotecan combination data to be presented at international oncology conference (ASX Announcement)

Sep 27th, 2023

Starpharma today announces the presentation of data that demonstrate the benefits of combining DEP^® irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in models of human colorectal cancer.

Starpharma featured on Bulls N' Bears

Sep 22nd, 2023

Starpharma interviewed for ausbiz

Sep 15th, 2023

Positive DEP® irinotecan clinical results to be presented at international oncology conference (ASX Announcement)

Sep 13th, 2023

Starpharma today announces positive interim results from its Phase 1/2 clinical trial of DEP^® irinotecan will be presented at the upcoming American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics in Boston, US, from 11 to 15 October 2023.

Change of Company Secretary (ASX Announcement)

Aug 28th, 2023

Starpharma today announces, in accordance with ASX Listing Rule 3.16.1, that Tracy Weimar has resigned as Company Secretary, a role that was conducted for an interim period.

Appendix 4G – Corporate Governance Statement (ASX Announcement)

Aug 24th, 2023

Starpharma today releases its Appendix 4G – Key to Disclosures Corporate Governance Council Principles and Recommendations, in accordance with ASX Listing Rules 4.7.3 and 4.10.3.

Starpharma annual report and full-year financial results (ASX Announcement)

Aug 24th, 2023

Starpharma today releases its annual report and full-year financial results for the year ended 30 June 2023.

Starpharma to receive A$6.5M from Mundipharma and rights to VivaGel® BV (ASX Announcement)

Aug 14th, 2023

Starpharma today announces it has negotiated a commercial settlement agreement with Mundipharma in relation to the VivaGel^® BV product.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Jul 31st, 2023

Starpharma today releases its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2023 (Q4 FY23).

Partnered program update (ASX Announcement)

Jul 31st, 2023

Following communication from AstraZeneca on Friday, 28 July 2023, and the subsequent release of AstraZeneca’s H1 and Q2 2023 results announcement that day, Starpharma (ASX: SPL, OTCQX: SPHRY) reports that AstraZeneca has made the decision to discontinue the development of AZD0466, after an internal review, prompted by a small number of asymptomatic adverse events (AEs) that were unrelated to Starpharma’s dendrimer drug delivery technology.

Starpharma partners with UQ to advance DEP® radio pipeline (ASX Announcement)

Jul 26th, 2023

Starpharma today announces it has entered a new partnership with The University of Queensland’s (UQ’s) Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR Hub), which has been awarded $4.8 million from the Australian Government’s Australian Research Council (ARC).

DEP® HER2-radiodiagnostic shows imaging benefits (ASX Announcement)

Jul 21st, 2023

Starpharma today announces that DEP^® HER2-zirconium, its HER2-targeted radiodiagnostic candidate, has demonstrated a favourable biodistribution profile, with excellent imaging contrast between tumour and normal tissues, as well as rapid uptake and high levels of tumour accumulation in a HER+ breast cancer model.

Clinical trial update (ASX Announcement)

Jun 27th, 2023

A voluntary partial clinical hold has been implemented on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419).

Life Sciences Investor Presentation (ASX Announcement)

Jun 23rd, 2023

Further to yesterday’s announcement, Starpharma (ASX: SPL, OTCQX: SPHRY) provides a copy of the investor presentation that was aired during the OTCQX’s Virtual Life Sciences Investor Forum on Thursday, 22 June 2023 at 10:00 am EDT (Friday, 23 June 2023, at 12:00 am AEST).

Starpharma to present at Life Sciences Investor Forum (ASX Announcement)

Jun 22nd, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that an investor presentation by Chief Executive Officer, Dr Jackie Fairley, will be broadcast at 10:00 am EDT on Thursday, 22 June 2023 (12:00 am AEST on Friday, 23 June 2023), as part of the OTCQX’s Virtual Life Sciences Investor Forum.

AZD0466 clinical data presented by AstraZeneca at EHA Congress (ASX Announcement)

Jun 14th, 2023

Starpharma today announces the presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress (EHA Congress), which was held from 8 - 11 June 2023.

Starpharma CEO to retire in 2024 (ASX Announcement)

Jun 9th, 2023

Starpharma (ASX: SPL, OTCQX: SPHRY) wishes to advise that following her significant tenure as the Company’s Chief Executive Officer (CEO), Dr Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.

Commencement of CFO and Company Secretary (ASX Announcement)

Apr 3rd, 2023

Melbourne, Australia; 3 April 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that, further to the announcement on 3 March 2023, Mr Justin Cahill commences in the role of Chief Financial Officer (CFO) and Company Secretary today. 

Starpharma presents at ASX Small and Mid-Cap Conference (ASX Announcement)

Mar 22nd, 2023

Melbourne, Australia; 22 March 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces that Starpharma CEO Dr Jackie Fairley will present a brief overview of the Company at the ASX Small and Mid-Cap Conference today at 11:00am AEDT. The Conference showcases selected ASX-listed companies to Australian investors.

CFO and Company Secretary Appointment (ASX Announcement)

Mar 3rd, 2023

Melbourne, Australia; 3 March 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Mr Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process. Justin will commence in the role in early April 2023.

Interim Report and Half-Year Financial Results - H1FY23 (ASX Announcement)

Feb 28th, 2023

Melbourne, Australia; 28 February 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its interim report and half-year financial results for the period ended 31 December 2022 (H1 FY23).

Appointment of Company Secretary (ASX Announcement)

Feb 1st, 2023

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises, in accordance with ASX Listing Rule 3.16.1, that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective today.

Dr Russell Basser appointed as non-executive director (ASX Announcement)

Jan 31st, 2023

The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.

Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.

Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.